RE: A longer post on valuation...6 Mar 2023 16:41
To repeat:
Wasn't Trodelvy (Immuno's lead drug) in Phase 3 trials? Hadn't it, in fact, already passed a phase 3 trial re patients with advanced mTNBC?
Slightly misleading to compare the two, one might argue. Then again, unsurprising given your continuous and desperate attempts to prop up your frankly ludicrous predictions and summations.